CTIS2022-502869-17-00进行中（未招募）1 期
FusionVAC22_01
niversitaetsklinikum Tuebingen0 个研究点目标入组 20 人开始时间: 2023年2月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusiofibrolamellar hepatocellular carcinoma, tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACACTIS2022-502869-17-01niversitaetsklinikum Tuebingen20
招募中
1 期
A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumorsPatients with breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma.MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2022-500902-16-00Philogen S.p.A.20
进行中（未招募）
1 期
A study to investigate VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2024-514339-87-00VarmX B.V.12
招募中
1 期
Study of safety, tolerability and efficacy of DFV890 in participants with myeloid diseasesCTIS2022-501406-36-00ovartis Pharma AG80
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced MalignanciesAdvanced MalignanciesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-514010-12-00Invox Pharma Limited131